Zoetis (ZTS) is currently drawing the focus of varying investors, with numerous securities firms performing buys, sells, or holds to their Zoetis holdings.
Significant purchases of Zoetis shares have been made by entities such as Carnegie Lake Advisors, Verdence Capital Advisors, Pictet Asset Management, and many of several wealth management firms. This occurs as some investors have lessened their shares, including Kestra Private Wealth Services, Segall Bryant & Hamill, and Ownership Capital. Despite recent downgrades by analysts from a market outperform to perform, bullish sentiments continue to surround ZTS, particularly due to expected strong growth in Zoetis' market performance. Argus, while reducing the price target for ZTS, maintains a
constructive view. Delivering on earnings estimates has been a strong suit for Zoetis, consecutively beating expectations. Opinions on Zoetis' future persist as generally positive, with numerous parties encouraging investment. Anticipations for their next earnings report stay high as well. However, factors such as the slow launch of Librela and market competition have sparked concern. As the global leader in animal healthcare, Zoetis seeks to strengthen its position through continued growth.
Zoetis ZTS News Analytics from Wed, 22 Jan 2025 08:00:00 GMT to Sat, 19 Jul 2025 14:39:51 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -2
